All In Biotech

Drug Trial Radar · NCT04171700

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes

Last checked: Nov 20, 2026Latest source record: Oct 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

83

Actual

Start

Jan 16, 2020

Primary completion

Jun 8, 2022

Study completion Jul 15, 2022

Sponsor

Lead sponsor
pharmaand GmbHIndustry
Sponsor type
Industry
First posted
Nov 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

Conditions

  • Solid Tumor

Interventions

  • RucaparibDrug

    Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate by InvestigatorTime frame: From first dose of study drug until disease progression (up to approximately 2 years)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medicine Hematology and Oncology

    Los Angeles, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Beth Israel Deaconess Medical Cancer Surgical Pavilion

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Columbia University Irving Medical Center

    New York, New York

  • New York Cancer and Blood Specialists

    Port Jefferson Station, New York

  • New York Cancer And Blood Specialists

    The Bronx, New York

  • Ohio State University

    Columbus, Ohio

  • Stephenson Cancer Center - The University of Oklahoma

    Oklahoma City, Oklahoma

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • SCRI/Tennessee Oncology - Chattanooga

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Seattle Cancer Care Alliance/University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.